Nykjaer A, Bengtsson-Olivecrona G, Lookene A, Moestrup S K, Petersen C M, Weber W, Beisiegel U, Gliemann J
Institute of Medical Biochemistry, University of Aarhus, Denmark.
J Biol Chem. 1993 Jul 15;268(20):15048-55.
Lipoprotein lipase (LPL) causes a marked increase in the cellular binding of beta-migrating very low density lipoprotein (beta-VLDL) to a large receptor compatible with the alpha 2-macroglobulin receptor (alpha 2MR)/low density lipoprotein receptor-related protein (LRP) (Beisiegel, U., Weber, W., and Bengtsson-Olivecrona, G. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 8342-8346). Here we demonstrate that LPL binds to the alpha-chain of purified alpha 2MR/LRP immobilized on microtiter plates. The binding, apparently to multiple sites, was blocked by heparin and inhibited by the alpha 2MR-associated protein (alpha 2MRAP) and by EDTA. Immobilized LPL bound alpha 2MR/LRP in solution as well as beta-VLDL prepared from cholesterol-fed rabbits. Both binding reactions were dependent on an intact carboxyl-terminal folding domain of LPL, but were independent of its dimeric structure and intact catalytical function. Dimeric LPL could mediate binding of beta-VLDL to immobilized alpha 2MR/LRP and to cells, e.g. monocytes. In contrast, LPL monomers were not able to mediate binding to immobilized alpha 2MR/LRP, presumably because of cross-inhibition due to close relation between the binding regions for the lipoprotein and for the receptor in the carboxyl-terminal domain of the LPL monomer. Heparin, but not alpha 2MRAP, inhibited cellular binding of 125I-LPL or 125I-beta-VLDL supplemented with LPL. However, alpha 2MRAP inhibited degradation of the two ligands by about 90% and 40-50%, respectively. The results show that LPL is a ligand for alpha 2MR/LRP and, because of its affinity for lipoprotein particles, dimeric LPL can mediate or strengthen binding of beta-VLDL to this receptor. It is proposed that LPL binds primarily to cell surface heparan sulfate in monocytes and is presented for endocytosis and degradation by alpha 2MR/LRP. Moreover, beta-VLDL may be further supplemented with LPL at the cell surface and achieve affinity for alpha 2MR/LRP.
脂蛋白脂肪酶(LPL)可使β迁移极低密度脂蛋白(β-VLDL)与一种与α2-巨球蛋白受体(α2MR)/低密度脂蛋白受体相关蛋白(LRP)兼容的大型受体的细胞结合显著增加(贝西格尔,U.,韦伯,W.,和本特松-奥利韦克隆纳,G.(1991年)《美国国家科学院院刊》88,8342 - 8346)。在此我们证明,LPL可与固定在微量滴定板上的纯化α2MR/LRP的α链结合。这种结合显然是多位点的,可被肝素阻断,并被α2MR相关蛋白(α2MRAP)和EDTA抑制。固定化的LPL能结合溶液中的α2MR/LRP以及由胆固醇喂养的兔子制备的β-VLDL。两种结合反应均依赖于LPL完整的羧基末端折叠结构域,但与其二聚体结构和完整的催化功能无关。二聚体LPL可介导β-VLDL与固定化α2MR/LRP以及细胞(如单核细胞)的结合。相比之下,LPL单体无法介导与固定化α2MR/LRP的结合,推测是由于LPL单体羧基末端结构域中脂蛋白结合区域与受体结合区域关系密切导致的交叉抑制。肝素而非α2MRAP可抑制补充有LPL的125I-LPL或125I-β-VLDL的细胞结合。然而,α2MRAP分别使两种配体的降解约减少90%和40 - 50%。结果表明,LPL是α2MR/LRP的一种配体,并且由于其对脂蛋白颗粒的亲和力,二聚体LPL可介导或增强β-VLDL与该受体的结合。有人提出,LPL主要与单核细胞表面的硫酸乙酰肝素结合,并被α2MR/LRP摄取进行内吞和降解。此外,β-VLDL在细胞表面可能会进一步补充LPL,并获得对α2MR/LRP的亲和力。